Postconditioning used for the limitation of infarct size in patients with ST-elevation myocardial infarction (POSTCON). - POSTCON

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-001221-10-DK

Enrollment

200

Registered

2008-09-25

Start date

2008-11-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with ST-segment elevation myocardial infarction (STEMI) are routinely treated with primary PCI (pPCI) as a world wide standard. Glucagon like peptide (GLP1) is a genuine hormone created in the gut and with well characterized receptors in heart muscle. Previous studies have proven it to be safe in human and intravenous administration for 72 hours have shown it to reduce infarct size in pPCI.

Interventions

Trade Name: byetta Pharmaceutical Form: Solution for injection INN or Proposed INN: exenatid Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients > 18 years submitted for acut pPCI because of STEMI. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Multivessel disease. Lesions that can not be treated with stent. Previous Q-wave MI. Impaired renal function. Previous CABG. Pregnancy. Diabetic ketoacidosis or hypoglycemia (plasma glucose < 3.3. mmol/l).

Design outcomes

Primary

Measure	Time frame
Main Objective: After reopening of the infarct related artery by pPCI, patients are randomized to either GLP-1 or saline administration as one intracoronary bolus. The administration is done by means of the guiding catheter that is also used for the pPCI. Following 4 weeks magnetic resonnance (MR) is used to evaluta whether GLP-1 has reduced final infarct size, which is expected. ;Secondary Objective: To evaluate if GLP1 reduces major cardiovascular endpoints (death, reinfarction, re-intervention on target vessel).;Primary end point(s): Infarct size by MR, echocardiography and enzymemarker elevation.	—

Measure

Time frame

Main Objective: After reopening of the infarct related artery by pPCI, patients are randomized to either GLP-1 or saline administration as one intracoronary bolus. The administration is done by means of the guiding catheter that is also used for the pPCI. Following 4 weeks magnetic resonnance (MR) is used to evaluta whether GLP-1 has reduced final infarct size, which is expected. ;Secondary Objective: To evaluate if GLP1 reduces major cardiovascular endpoints (death, reinfarction, re-intervention on target vessel).;Primary end point(s): Infarct size by MR, echocardiography and enzymemarker elevation.

—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026